Madunić IV, Madunić J, Breljak D, Karaica D, Sabolić I. Sodium-glucose cotransporters: new targets of cancer therapy? Arh Hig Rada Toksikol. 2018;69(4):278–85.

Article  PubMed  Google Scholar 

Basak D, Gamez D, Deb S. SGLT2 inhibitors as potential anticancer agents. Biomedicines. 2023;11(7):1867.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res. 2001;92:874–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA. 2015;112:E4111–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright EM. SGLT2 and cancer. Pflügers Arch Eur J Physiol. 2020;472:1407–14.

Article  CAS  Google Scholar 

Fujiyoshi S, Honda S, Ara M, Kondo T, Kobayashi N, Taketomi A. SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma. J Hepatobiliary Pancreat Sci. 2023

Kobayashi M, Uematsu T, Tokura Y, Takei K, Sakamoto K, Narimatsu T, et al. Immunohistochemical expression of Sodium-Dependent Glucose Transporter-2 (SGLT-2) in clear cell renal carcinoma: Possible prognostic implications. Int Braz J Urol. 2019;45:169–78.

Article  PubMed  PubMed Central  Google Scholar 

Forzano I, Wilson S, Lombardi A, Jankauskas SS, Kansakar U, Mone P, Varzideh F, Santulli G. SGLT2 inhibitors: an evidence-based update on cardiovascular implications. Expert Opin Investig Drugs. 2023;32(9):839–847.

Colloca A, Donisi I, Anastasio C, Balestrieri ML, D’Onofrio N. Metabolic alteration bridging the prediabetic state and colorectal cancer. Cells. 2024;13(8):663.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7):3651.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12(2):78–89.

Article  CAS  PubMed  Google Scholar 

Marfella R, D’Onofrio N, Trotta MC, Sardu C, Scisciola L, Amarelli C, et al. Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism. 2022;127: 154936.

Article  CAS  PubMed  Google Scholar 

Santulli G, Varzideh F, Forzano I, Wilson S, Salemme L, de Donato A, Lombardi A, Rainone A, Nunziata L, Jankauskas SS, Tesorio T, Guerra G, Kansakar U, Mone P. Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart. Hypertension. 2023;80(9):1800–9.

Article  CAS  PubMed  Google Scholar 

D’Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, et al. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment. Mol Metab. 2021;54: 101337.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1):98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704.

Article  CAS  PubMed  Google Scholar 

Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26(1):27–38.

Article  CAS  PubMed  Google Scholar 

Naznin F, Sakoda H, Okada T, Tsubouchi H, Waise TM, Arakawa K, Nakazato M. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur J Pharmacol. 2017;794:37–44.

Article  CAS  PubMed  Google Scholar 

Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941–50.

Article  CAS  PubMed  Google Scholar 

Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, Erondu N. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40(5):632–9.

Article  CAS  PubMed  Google Scholar 

Benedetti R, Benincasa G, Glass K, Chianese U, Vietri MT, Congi R, Altucci L, Napoli C. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res. 2022;175: 106039.

Article  CAS  PubMed  Google Scholar 

Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X, Xu Y, Feng J, Yuan M, Gao X, Wang J, Xu X, Li S, Wu H, Cao J, He Q, Yang B. Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J Clin Invest. 2023;133(1): e154754.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saito T, Okada S, Yamada E, Shimoda Y, Osaki A, Tagaya Y, et al. Effect of dapagliflozin on colon cancer cell [Rapid Communication]. Endocr J. 2015;62(12):1133–7.

Article  CAS  PubMed  Google Scholar 

Wei Q, Qian Y, Yu J, Wong CC. Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications. Oncogene. 2020;39(39):6139–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

van den Berg I, Coebergh van den Braak RRJ, van Vugt JLA, Ijzermans JNM, Buettner S. Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study. World J Surg Oncol. 2021;19(1):96.

Article  PubMed  PubMed Central  Google Scholar 

Pakiet A, Kobiela J, Stepnowski P, Sledzinski T, Mika A. Changes in lipids composition and metabolism in colorectal cancer: a review. Lipids Health Dis. 2019;18(1):29.

Article  PubMed  PubMed Central  Google Scholar 

La Vecchia S, Sebastián C. Metabolic pathways regulating colorectal cancer initiation and progression. Semin Cell Dev Biol. 2020;98:63–70.

Article  PubMed  Google Scholar 

Park JH, Pyun WY, Park HW. Cancer metabolism: phenotype, signaling and therapeutic targets. Cells. 2020;9(10):2308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121(1):29–40.

Article  CAS  PubMed  Google Scholar 

Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784–94.

Article  CAS  PubMed  Google Scholar 

Yang X, Liu Q, Li Y, Tang Q, Wu T, Chen L, et al. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway. Adipocyte. 2020;9(1):484–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5(10):1048–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ali A, Mekhaeil B, Biziotis OD, Tsakiridis EE, Ahmadi E, Wu J, et al. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun Biol. 2023;6(1):919.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biziotis OD, Tsakiridis EE, Ali A, Ahmadi E, Wu J, Wang S, et al. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. Mol Oncol. 2023;17(11):2235–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Zhai J, Zhang T, He L, Ma S, Zuo Q, et al. Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress. Biochem Biophys Res Commun. 2023;653:53